EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial

Laya Hooshmand Gharabagh iD, Mehdi Heydaroghli iD, Ayda Esmaeili iD

Archives of Iranian Medicine · 2025

DOI: 10.34172/aim.33355 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Archives of Iranian Medicine, 2025. Verfasst von Laya Hooshmand Gharabagh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Imam Khomeini Hospital, Urmia, Iran. Hauptthemen laut MEDLINE: Acetylcysteine, Diabetic Foot, Osteomyelitis, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biofilm formation by bacteria on the lower limb arises from reduced peripheral arterial blood flow, which can lead to the failure of antibiotic therapy or require longer duration of intravenous antibiotic therapy in diabetic foot infection-associated osteomyelitis. N-acetyl cysteine (NAC), an agent known to prevent and treat biofilm-related infections, was used as a novel strategies beside antibiotic therapy in osteomyelitis of diabetic foot with the aim of accelerating the response to antibiotic therapy regimen.

Methods

To assess the synergistic effect of NAC with antibiotic therapy, patients with diabetic foot osteomyelitis (DFO) (grade III or IV Wagner) were randomly assigned to either NAC 600 mg effervescent tablet twice daily for 2 weeks or the control group. Clinical and laboratory data, including white blood cell with differentiation and inflammatory factors (ESR and CRP) were measured at baseline (time 0), after one week and after three weeks of initiating the intervention.

Results

Fifty-three eligible patients completed the study. All evaluated infectious-related laboratory parameters showed significant reductions in the NAC group compared to control (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetylcysteineDiabetic FootOsteomyelitisAnti-Bacterial AgentsHumansMaleFemaleMiddle AgedAgedTreatment OutcomeC-Reactive ProteinAdultBlood SedimentationChemotherapy, Adjuvant

Stichwörter der Autor:innen

Diabetic foot osteomyelitisInflammatory markersN-acetyl cysteineOptimizing treatment response

Substanzen

AcetylcysteineAnti-Bacterial AgentsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Imam Khomeini Hospital, Urmia, Iran.
  • Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.
  • Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.

ORCID-Profile: Laya Hooshmand Gharabagh, Mehdi Heydaroghli, Ayda Esmaeili

Zitieren

APA

Hooshmand Gharabagh, L., Heydaroghli, M., & Esmaeili, A. (2025). Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial. Archives of Iranian Medicine. https://doi.org/10.34172/aim.33355

Vancouver

Hooshmand Gharabagh L, Heydaroghli M, Esmaeili A. Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial. Archives of Iranian Medicine. 2025. doi:10.34172/aim.33355

BibTeX
@article{HooshmandGharabagh2025,
  author = {Hooshmand Gharabagh, Laya and Heydaroghli, Mehdi and Esmaeili, Ayda},
  title = {Efficacy Of N-Acetyl-Cysteine as Adjuvant Therapy for Diabetic Foot Osteomyelitis: An Open-Label Randomized Controlled Trial},
  journal = {Archives of Iranian Medicine},
  year = {2025},
  doi = {10.34172/aim.33355}
}
Kostenlos starten →